BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 52-Week Low – What’s Next?

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) reached a new 52-week low during trading on Tuesday . The company traded as low as $7.53 and last traded at $7.4950, with a volume of 195346 shares traded. The stock had previously closed at $7.78.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen cut BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 price objective for the company. HC Wainwright boosted their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Finally, Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $23.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BridgeBio Oncology Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

BridgeBio Oncology Therapeutics Stock Performance

The stock’s 50-day simple moving average is $8.62. The stock has a market capitalization of $593.21 million, a PE ratio of -3.61 and a beta of 0.29.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. As a group, equities analysts expect that BridgeBio Oncology Therapeutics, Inc will post -2.32 EPS for the current year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth about $63,000. Persistent Asset Partners Ltd acquired a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at $144,000. Quadrature Capital Ltd acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth $162,000. Finally, BIT Capital GmbH bought a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth $313,000. 54.89% of the stock is owned by institutional investors and hedge funds.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.